Dicerna Pharmaceuticals, Inc. (DRNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dicerna Pharmaceuticals, Inc. (DRNA) trades at $38.22 with AI Score 46/100 (Grade C). Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for DRNA: DRNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DRNA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DRNA: 1/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Dicerna Pharmaceuticals, Inc. (DRNA) Healthcare & Pipeline Overview
Dicerna Pharmaceuticals, a subsidiary of Novo Nordisk, leverages its GalXC RNAi platform to develop innovative therapies for liver diseases, cardiometabolic disorders, and neurodegenerative conditions. The company's strategic collaborations and focus on RNAi technology position it within the competitive biotechnology sector, addressing unmet medical needs.
What Is the Investment Thesis for DRNA?
Dicerna Pharmaceuticals, now a subsidiary of Novo Nordisk, presents a focused investment opportunity within the RNAi therapeutics space. The company's GalXC platform offers a competitive advantage in developing targeted therapies for liver-related diseases. Key value drivers include the continued advancement of its pipeline programs, such as nedosiran and RG6346, and the potential for future collaborations leveraging the GalXC technology. The company's high gross margin of 100% indicates strong potential profitability upon successful commercialization of its products. However, the company's negative profit margin of -68.6% reflects ongoing R&D investments. Upcoming clinical trial results and regulatory milestones for its key drug candidates will serve as significant catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from other RNAi therapeutics companies.
Based on FMP financials and quantitative analysis
DRNA Key Highlights
Dicerna Pharmaceuticals operates as a subsidiary of Novo Nordisk A/S since December 27, 2021, providing financial stability and resources.
- The company's GalXC RNAi platform enables the development of targeted therapies for liver-related diseases, offering a competitive edge.
- Dicerna has a 100.0% gross margin, indicating strong potential profitability upon successful commercialization of its products.
- Strategic collaborations with major pharmaceutical companies like Roche and Eli Lilly validate Dicerna's technology and pipeline.
- Key development programs include nedosiran for primary hyperoxaluria and RG6346 for chronic hepatitis B virus infection, addressing significant unmet medical needs.
Who Are DRNA's Competitors?
DRNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CBAY CymaBay Therapeutics | $32.48 | +0.03% | $3.73B | 59 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DRNA's Key Strengths?
Proprietary GalXC RNAi platform for targeted gene silencing.
- Strategic collaborations with major pharmaceutical companies.
- Focus on liver-related diseases with high unmet medical need.
- Strong intellectual property portfolio.
What Are DRNA's Weaknesses?
High R&D expenses and negative profit margin.
- Reliance on collaborations for funding and commercialization.
- Clinical trial risks and regulatory hurdles.
- Limited number of commercialized products.
What Could Drive DRNA Stock Higher?
Clinical trial results for nedosiran in primary hyperoxaluria.
- Regulatory submissions for key drug candidates.
- Advancement of RG6346 for chronic hepatitis B virus infection in collaboration with Roche.
- Expansion of GalXC platform to new therapeutic areas.
What Are the Key Risks for DRNA?
Negative return on equity (-77.8%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures and regulatory setbacks.
- Competition from other RNAi therapeutics companies.
- Patent expiration and generic competition.
- High R&D expenses and negative profit margin.
- Reliance on collaborations for funding and commercialization.
What Are the Growth Opportunities for DRNA?
- Expansion of GalXC RNAi Platform: Dicerna can leverage its GalXC platform to develop new therapies for a broader range of diseases beyond liver-related conditions. The global RNAi therapeutics market is projected to reach $1.39 billion by 2028, growing at a CAGR of 14.5% from 2021, presenting a significant opportunity for Dicerna to expand its pipeline and market reach. This expansion can be achieved through internal research and development efforts, as well as strategic collaborations with other companies.
- Advancement of Nedosiran for Primary Hyperoxaluria: Nedosiran, Dicerna's lead product candidate for the treatment of primary hyperoxaluria (PH), represents a significant growth opportunity. PH is a rare genetic disorder with limited treatment options, creating a high unmet medical need. Successful completion of clinical trials and regulatory approval for nedosiran could generate substantial revenue for Dicerna. The market for PH treatments is estimated to reach $300 million by 2027, providing a clear target for Dicerna's commercialization efforts.
- Development of RG6346 for Chronic Hepatitis B Virus Infection: RG6346, being developed in collaboration with Roche, targets chronic hepatitis B virus (HBV) infection. HBV affects millions of people worldwide, and there is a need for more effective and durable treatments. Successful development and commercialization of RG6346 could generate significant revenue for Dicerna. The global market for HBV treatments is projected to reach $3.5 billion by 2028, offering a substantial opportunity for Dicerna.
- Strategic Collaborations and Partnerships: Dicerna can continue to pursue strategic collaborations and partnerships with other pharmaceutical companies to expand its pipeline and access new markets. Collaborations can provide Dicerna with access to additional funding, expertise, and resources, accelerating the development and commercialization of its RNAi therapeutics. The company's existing collaborations with Novo Nordisk, Roche, and Eli Lilly demonstrate its ability to attract and maintain valuable partnerships.
- Expansion into New Therapeutic Areas: Dicerna can leverage its GalXC platform to expand into new therapeutic areas beyond liver-related diseases, such as oncology, neurology, and immunology. The RNAi technology has the potential to target a wide range of diseases, providing Dicerna with numerous opportunities to diversify its pipeline and address unmet medical needs. This expansion can be achieved through internal research and development efforts, as well as strategic acquisitions of other companies with complementary technologies.
What Are DRNA's Competitive Advantages?
- Proprietary GalXC RNAi platform: Enables targeted gene silencing with enhanced delivery to the liver.
- Strategic collaborations with major pharmaceutical companies: Provides access to funding, expertise, and resources.
- Strong intellectual property portfolio: Protects its RNAi technology and drug candidates.
- Focus on liver-related diseases: Addresses a significant unmet medical need with targeted therapies.
What Does DRNA Do?
Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts. The company is focused on the discovery, development, and commercialization of innovative ribonucleic acid interference (RNAi)-based pharmaceuticals. Dicerna's core technology is its proprietary GalXC RNAi platform, which is designed to silence specific genes that cause or contribute to disease. This platform enables the development of targeted therapies for a wide range of diseases, particularly those affecting the liver. Dicerna's pipeline includes programs targeting rare, cardiometabolic, viral, and chronic liver diseases, as well as complement-mediated diseases, neurodegenerative diseases, and pain. Key development programs include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, belcesiran for liver disease, and DCR-AUD for alcohol use disorder. Dicerna has established strategic collaborations with major pharmaceutical companies, including Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S, marking a significant milestone in its evolution and providing enhanced resources for its research and development efforts.
What Products and Services Does DRNA Offer?
- Discovers and develops RNAi-based pharmaceuticals.
- Utilizes the GalXC RNAi platform for targeted gene silencing.
- Focuses on treatments for liver-related diseases.
- Develops therapies for rare, cardiometabolic, and viral diseases.
- Addresses complement-mediated and neurodegenerative diseases.
- Collaborates with major pharmaceutical companies for drug development.
How Does DRNA Make Money?
- Develops RNAi-based therapeutics using its GalXC platform.
- Out-licenses its technology and drug candidates to pharmaceutical partners.
- Receives upfront payments, milestone payments, and royalties from collaborations.
- Focuses on research and development, with commercialization handled by partners.
What Industry Does DRNA Operate In?
Dicerna Pharmaceuticals operates within the biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The RNAi therapeutics market is a growing segment within the biotechnology industry, driven by the potential to develop highly targeted therapies for a wide range of diseases. Dicerna's GalXC platform positions it to compete with other companies in the RNAi space, such as Alnylam Pharmaceuticals. The industry is also influenced by trends such as personalized medicine, gene editing technologies, and increasing demand for novel therapies for chronic diseases.
Who Are DRNA's Key Customers?
- Novo Nordisk A/S (parent company)
- F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
- Eli Lilly and Company
- Alnylam Pharmaceuticals, Inc.
- Alexion Pharmaceuticals, Inc.
- Boehringer Ingelheim International GmbH
Key Financial Metrics
Return on equity for Dicerna Pharmaceuticals, Inc. stands at -77.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.9%, showing how much profit it generates from its asset base. A current ratio of 3.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.0%, the inverse of the P/E and a quick read on earnings relative to price.
DRNA Valuation & Market Position
Relative to its peer group, DRNA's quantitative score of 46/100 is below the peer average of 84/100.
Company Profile
Dicerna Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Douglas Fambrough. DRNA has traded publicly since 2014.
DRNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence from those closest to the company, suggesting they believe the stock is undervalued.
- The community sentiment seems to be leaning bullish, with many expressing optimism about the company's long-term prospects and potential partnerships.
- Market perception indicates a growing interest in RNAi therapeutics, which could benefit Dicerna as a key player in this space.
- Positive developments in the broader pharmaceutical sector are creating a favorable environment for companies like Dicerna, potentially attracting more investment.
Bear Case
- Insider activity, while showing some buying, might not fully reflect the overall financial health of the company and could be opportunistic.
- Despite bullish sentiment, some community members express concerns about the company's cash burn rate and the need for future funding.
- Market perception also reveals skepticism regarding the regulatory hurdles and clinical trial risks associated with RNAi therapies.
- Broader market volatility and potential economic downturns could negatively impact smaller biotech companies like Dicerna, reducing investor appetite.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DRNA Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Dec 13, 2019
DRNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DRNA.
Price Targets
Wall Street price target analysis for DRNA.
DRNA MoonshotScore
What does this score mean?
The MoonshotScore rates DRNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Douglas Fambrough
CEO
Douglas Fambrough served as the CEO of Dicerna Pharmaceuticals, Inc. He has a strong background in the biotechnology industry, with extensive experience in venture capital and company building. Prior to joining Dicerna, he was a general partner at Atlas Venture, where he focused on investments in early-stage biotechnology companies. He holds a Ph.D. in genetics from Harvard University and a B.S. in biology from Cornell University. His expertise spans drug discovery, development, and commercialization.
Track Record: Under Douglas Fambrough's leadership, Dicerna Pharmaceuticals advanced its GalXC RNAi platform and developed a pipeline of promising drug candidates. He oversaw strategic collaborations with major pharmaceutical companies, including Novo Nordisk, Roche, and Eli Lilly. A key achievement was the acquisition of Dicerna by Novo Nordisk in December 2021, which validated the company's technology and provided enhanced resources for its research and development efforts.
Dicerna Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for DRNA?
DRNA holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. Acquired by Novo Nordisk A/S in December 2021, Dicerna focuses on developing …
What does Dicerna Pharmaceuticals, Inc. do?
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing RNA interference (RNAi)-based therapeutics. Utilizing its proprietary GalXC RNAi platform, Dicerna targets genes that cause or contribute to various diseases, particularly those affecting the liver. The company's pipeline includes programs addressing rare, cardiometabolic, viral, and chronic liver diseases.
What do analysts say about DRNA stock?
As of December 2021, Dicerna Pharmaceuticals, Inc. was acquired by Novo Nordisk A/S. Prior to the acquisition, analyst ratings and price targets reflected expectations for the company's pipeline progress and potential commercial success. Key valuation metrics focused on the potential revenue from its lead drug candidates, such as nedosiran and RG6346.
What are the main risks for DRNA?
Dicerna Pharmaceuticals, now a subsidiary of Novo Nordisk, faces several potential risks. Clinical trial failures and regulatory setbacks remain significant concerns, as the development of new therapeutics is inherently uncertain. Competition from other RNAi therapeutics companies also poses a threat. Patent expiration and generic competition could impact the long-term profitability of its products.
What are the key factors to evaluate for DRNA?
Dicerna Pharmaceuticals, Inc. (DRNA) holds an AI score of 46/100 (low). Dicerna Pharmaceuticals, now a subsidiary of Novo Nordisk, presents a focused investment opportunity within the RNAi therapeutics space. Not financial advice.
How frequently does DRNA data refresh on this page?
DRNA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DRNA's recent stock price performance?
Dicerna Pharmaceuticals, Inc. (DRNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary GalXC RNAi platform for targeted gene silencing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DRNA overvalued or undervalued right now?
Dicerna Pharmaceuticals, Inc. (DRNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research DRNA before investing?
Before investing in Dicerna Pharmaceuticals, Inc. (DRNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on data available up to the acquisition of Dicerna Pharmaceuticals, Inc. by Novo Nordisk A/S in December 2021.